Non Psychotropic Hemp Oil
Also known as: Non-psychotropic hemp oil, Hemp seed oil, Cannabidiol oil, CBD oil, Cannabidiol (CBD)
Overview
Non-psychotropic hemp oil is derived from *Cannabis sativa* L. plants specifically bred to contain negligible levels of tetrahydrocannabinol (THC), the psychoactive compound. Its primary active component is cannabidiol (CBD), a non-psychoactive phytocannabinoid. This oil is typically extracted from the flowers and aerial parts of the hemp plant, rather than just the seeds, to maximize CBD content. It is classified as a nutraceutical, botanical extract, or cannabinoid supplement. Users seek it for its potential anti-inflammatory, anxiolytic, analgesic, and neuroprotective properties, with emerging interest in its role in gastrointestinal health and sleep improvement. CBD oil is characterized by its non-psychoactive nature, general tolerability, and its interaction with the body's endocannabinoid system without causing intoxication. Research on CBD is extensive, including numerous randomized controlled trials and meta-analyses, indicating a moderate to high level of research maturity and quality, particularly for conditions like epilepsy and anxiety.
Benefits
Non-psychotropic hemp oil, primarily through its CBD content, offers several evidence-based benefits. It demonstrates significant anti-inflammatory and analgesic effects, with some randomized controlled trials showing reductions in pain and inflammation markers, though effect sizes can vary. A meta-analysis highlighted CBD's good tolerability and potential efficacy signals in non-epilepsy conditions. For sleep improvement, low doses of CBD may enhance sleep quality, although these effects are often modest and comparable to or less than those of low-dose melatonin. CBD also exhibits anxiolytic and mood-stabilizing properties, supported by both clinical and preclinical studies. Secondary benefits include potential modulation of the endocannabinoid system in gastrointestinal disorders, though clinical data in this area are still limited. The strongest evidence for benefits is observed in populations with epilepsy and anxiety, with growing data for chronic pain and sleep disorders. While some meta-analyses report non-significant differences versus placebo for certain outcomes, the overall safety profile is favorable, and benefits typically manifest over weeks to months of consistent use.
How it works
Non-psychotropic hemp oil primarily exerts its effects by modulating the endocannabinoid system (ECS), a complex network involved in regulating various physiological processes. While CBD has low direct affinity for the classical cannabinoid receptors (CB1 and CB2), it acts indirectly on the ECS. Its mechanisms include inhibiting the fatty acid amide hydrolase (FAAH) enzyme, which increases levels of the endocannabinoid anandamide. CBD also interacts with other non-cannabinoid receptors and ion channels, such as serotonin 5-HT1A receptors, transient receptor potential vanilloid 1 (TRPV1) channels, and peroxisome proliferator-activated receptor gamma (PPARγ) nuclear receptors. These interactions contribute to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective effects. The ECS is widely distributed throughout the central nervous system, immune system, and gastrointestinal tract, explaining the broad range of CBD's potential therapeutic applications. Oral bioavailability of CBD is relatively low (6-19%) due to first-pass metabolism, but sublingual or inhaled administration can improve absorption.
Side effects
Non-psychotropic hemp oil is generally well tolerated, with a favorable safety profile even with chronic use at low to moderate doses. The most common side effects, affecting more than 5% of users, include fatigue, diarrhea, and changes in appetite or weight. Less common side effects, occurring in 1-5% of individuals, may include dry mouth, dizziness, and somnolence. Rare side effects, observed in less than 1% of users, can involve elevated liver enzymes, which necessitates caution and monitoring, especially in individuals with pre-existing liver conditions or those taking other hepatotoxic medications. A significant concern is drug interactions, as CBD inhibits cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. This inhibition can alter the metabolism of numerous other medications, potentially leading to increased drug levels and adverse effects. Therefore, caution is advised for patients on medications metabolized by these enzymes. Contraindications include pregnancy and breastfeeding, as safety in these populations has not been established. In special populations, data are limited for children outside of epilepsy treatment, and elderly individuals may require dose adjustments due to altered metabolism.
Dosage
The optimal dosage of non-psychotropic hemp oil, primarily CBD, varies significantly depending on the individual and the specific condition being addressed. There is no single minimum effective dose, but clinical trials for anxiety or sleep often utilize daily doses ranging from 150 mg to 600 mg. For epilepsy, much higher doses are typically prescribed under medical supervision. For mild sleep improvement, lower doses, sometimes as little as 5-20 mg, are occasionally used. The maximum safe dose has been reported up to 1500 mg/day in some studies, but higher doses increase the risk of side effects. Timing considerations are important; dividing the daily dose into multiple administrations may improve tolerability. The timing relative to meals can also affect absorption, with fatty meals generally enhancing oral bioavailability. Various forms exist, including oil tinctures, capsules, and sprays, each with differing absorption rates. Sublingual administration, for instance, bypasses first-pass metabolism, leading to better bioavailability compared to oral capsules. No specific cofactors are required, but consuming CBD with fatty foods can significantly enhance its absorption.
FAQs
Is non-psychotropic hemp oil safe?
Yes, it is generally considered safe with a favorable safety profile. Most side effects are mild, such as fatigue or diarrhea, and serious adverse events are rare, especially at recommended doses.
Will it cause a high?
No, non-psychotropic hemp oil contains negligible levels of THC (tetrahydrocannabinol), the psychoactive compound found in cannabis. Therefore, it does not produce intoxicating or 'high' effects.
How long does it take to see effects?
The time to observe effects can vary. For conditions like anxiety or sleep improvement, some individuals may notice changes within days to a few weeks, while chronic conditions might require longer, consistent use.
Can it interact with other medications?
Yes, CBD can interact with certain medications, particularly those metabolized by liver enzymes CYP3A4 and CYP2C19. It's crucial to consult a healthcare professional if you are taking other prescription drugs.
Is non-psychotropic hemp oil legal?
Non-psychotropic hemp oil containing less than 0.3% THC is legal in many jurisdictions, including the United States under federal law. However, legality can vary by country and even by state or local regulations, so it's important to check local laws.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7608221/ – This systematic review and meta-analysis of randomized controlled trials (RCTs) found that CBD is generally well tolerated with some efficacy signals across various conditions, noting no serious adverse effects. The study highlighted heterogeneity in dosing and populations across the included trials, but provided a high-quality assessment of CBD's safety and potential benefits.
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799017 – This meta-analysis of 20 RCTs involving 1459 individuals with pain revealed a significant placebo response in cannabinoid trials. It concluded that there was no clear superiority of cannabinoids over placebo in pain reduction, emphasizing the importance of the placebo effect and variable blinding quality in such studies. The study provides a moderate quality assessment of cannabinoid efficacy for pain.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7246936/ – This narrative review synthesized findings from various preclinical and clinical studies, indicating that CBD and other non-psychotropic cannabinoids possess anti-inflammatory, neuroprotective, and potential gastrointestinal benefits. It noted the limited clinical data for cannabinoids other than CBD, with much of the evidence being preclinical, thus providing a moderate quality assessment.
- https://www.tandfonline.com/doi/full/10.1080/27697061.2023.2203221 – This clinical study, though with a small sample size and lacking a placebo control, investigated chronic CBD users over several weeks. It found that low-dose CBD was safe and led to modest improvements in sleep quality, though these improvements did not exceed those observed with melatonin. The study offers limited but supportive data regarding CBD's safety and potential for sleep enhancement.
